Loading clinical trials...
Loading clinical trials...
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
Conditions
Interventions
Ra223
Enzalutamide
Locations
64
Belgium
Hopital Universitaire Brugmann
Brussels, Belgium
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
AZ Groeninge Kortrijk
Kortrijk, Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium
Start Date
October 1, 2015
Primary Completion Date
February 19, 2024
Completion Date
December 1, 2028
Last Updated
September 19, 2025
NCT06844383
NCT06594926
NCT06926283
NCT07177937
NCT06487507
NCT07004582
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions